Clinical Performance Evaluation of SARS-CoV-2 (COVID-19) Antigen Assay in Point of Care Settings

CompletedOBSERVATIONAL
Enrollment

232

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

June 1, 2022

Study Completion Date

June 1, 2022

Conditions
Covid-19
Interventions
DEVICE

SARS-CoV-2 Antigen Assay

To demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstrating that the assay can achieve a ≥ 80% sensitivity and specificity when it is compared to the results of a high sensitivity EUA SARSCoV-2 RT-PCR assay using nasopharyngeal samples.

Trial Locations (1)

21075

Centennial Medical, Elkridge

Sponsors
All Listed Sponsors
collaborator

CSSi Life Sciences

INDUSTRY

lead

Freedom For All Diagnostics

INDUSTRY

NCT05213897 - Clinical Performance Evaluation of SARS-CoV-2 (COVID-19) Antigen Assay in Point of Care Settings | Biotech Hunter | Biotech Hunter